MX2018009949A - Uso de una dieta que imita el ayuno para mejorar la eficacia de antiestrogenos en la terapia de cancer. - Google Patents

Uso de una dieta que imita el ayuno para mejorar la eficacia de antiestrogenos en la terapia de cancer.

Info

Publication number
MX2018009949A
MX2018009949A MX2018009949A MX2018009949A MX2018009949A MX 2018009949 A MX2018009949 A MX 2018009949A MX 2018009949 A MX2018009949 A MX 2018009949A MX 2018009949 A MX2018009949 A MX 2018009949A MX 2018009949 A MX2018009949 A MX 2018009949A
Authority
MX
Mexico
Prior art keywords
antiestrogens
efficacy
enhance
cancer therapy
mimicking diet
Prior art date
Application number
MX2018009949A
Other languages
English (en)
Inventor
Nencioni Alessio
Ballestrero Alberto
Odetti Patrizio
Monacelli Fiammetta
Caffa Irene
Longo Valter
Original Assignee
Univ Degli Studi Genova
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Degli Studi Genova filed Critical Univ Degli Studi Genova
Publication of MX2018009949A publication Critical patent/MX2018009949A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Un compuesto que tiene actividad antiestrogénica es usado en un método para el tratamiento de cáncer de mama (BC) u otros tumores que responden a estrógenos en un paciente humano, donde el método comprende someter al paciente a una dieta que imita el ayuno durante un periodo de 24 horas a 190 horas mientras el paciente esté siendo tratado con el compuesto que tiene actividad antiestrogénica, el cual puede ser un modulador del receptor de estrógeno selectivo (SERM), un desregulador del receptor de estrógeno selectivo (SERD) o un inhibidor de aromatasa (AI).
MX2018009949A 2016-02-18 2017-02-14 Uso de una dieta que imita el ayuno para mejorar la eficacia de antiestrogenos en la terapia de cancer. MX2018009949A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITUB2016A000828A ITUB20160828A1 (it) 2016-02-18 2016-02-18 Utilizzo di una dieta che mima il digiuno per potenziare l'efficacia di antiestrogeni nella terapia del cancro
PCT/EP2017/053209 WO2017140641A1 (en) 2016-02-18 2017-02-14 Use of a fasting mimicking diet to enhance the efficacy of antiestrogens in cancer therapy

Publications (1)

Publication Number Publication Date
MX2018009949A true MX2018009949A (es) 2019-03-06

Family

ID=55948993

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018009949A MX2018009949A (es) 2016-02-18 2017-02-14 Uso de una dieta que imita el ayuno para mejorar la eficacia de antiestrogenos en la terapia de cancer.

Country Status (14)

Country Link
US (1) US11963941B2 (es)
EP (1) EP3416632B1 (es)
JP (1) JP7071272B2 (es)
KR (1) KR20190003469A (es)
CN (1) CN109069451A (es)
AU (1) AU2017219830A1 (es)
BR (1) BR112018016820A2 (es)
CA (1) CA3014717C (es)
ES (1) ES2922284T3 (es)
IT (1) ITUB20160828A1 (es)
MX (1) MX2018009949A (es)
RU (1) RU2018129357A (es)
WO (1) WO2017140641A1 (es)
ZA (1) ZA201805418B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT201700008499A1 (it) 2017-01-26 2018-07-26 Univ Degli Studi Genova Composizione dietetica per la prevenzione e/o il trattamento dell’iperplasia dell’endometrio
WO2021126968A1 (en) * 2019-12-16 2021-06-24 University Of Southern California Utilization of a fasting-mimicking diet to reduce senescent cells and inflammation
IT202000008710A1 (it) 2020-04-23 2021-10-23 Ifom Fondazione St Firc Di Oncologia Molecolare Combinazione terapeutica per il trattamento del cancro della mammella
WO2024108336A1 (zh) * 2022-11-21 2024-05-30 中国科学院深圳先进技术研究院 抑制肿瘤细胞生长的方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998035036A1 (en) * 1997-02-10 1998-08-13 Genentech, Inc. Heregulin variants
US8211700B2 (en) * 2007-03-28 2012-07-03 University Of Southern California Induction of differential stress resistance and uses thereof
CN103562226A (zh) 2011-03-11 2014-02-05 梅里麦克制药股份有限公司 使用egfr家族受体的抑制剂来治疗激素难治性乳腺癌
EP3113776B1 (en) * 2014-03-06 2021-01-13 University of Southern California Use of short term starvation regimen in combination with kinase inhibitors to enhance traditional chemo-drug efficacy and feasibility and reverse side effects of kinases in normal cells and tissues

Also Published As

Publication number Publication date
US20190038591A1 (en) 2019-02-07
WO2017140641A1 (en) 2017-08-24
EP3416632B1 (en) 2022-04-13
ZA201805418B (en) 2019-11-27
JP7071272B2 (ja) 2022-05-18
AU2017219830A1 (en) 2018-08-30
BR112018016820A2 (pt) 2018-12-26
RU2018129357A (ru) 2020-03-18
ES2922284T3 (es) 2022-09-12
KR20190003469A (ko) 2019-01-09
JP2019505555A (ja) 2019-02-28
CA3014717A1 (en) 2017-08-24
CA3014717C (en) 2024-06-04
CN109069451A (zh) 2018-12-21
EP3416632A1 (en) 2018-12-26
ITUB20160828A1 (it) 2017-08-18
US11963941B2 (en) 2024-04-23
RU2018129357A3 (es) 2020-05-28

Similar Documents

Publication Publication Date Title
MX2021013830A (es) Inhibidores de ezh2 para tratar linfomas.
MX2020008906A (es) Compuestos con actividad inductora de ferroptosis y métodos de uso de estos.
MX2018009949A (es) Uso de una dieta que imita el ayuno para mejorar la eficacia de antiestrogenos en la terapia de cancer.
WO2020121310A3 (en) Method of treating cancer with a cancer therapy in combination with another therapeutic agent
MX2016017288A (es) Metodos para tratar el cancer con inhibidores de tigit y agentes contra el cancer.
WO2016025635A3 (en) Combination therapy for treating cancer
BR112016017700A2 (pt) método para tratamento de um câncer em um indivíduo, medicamento, kit, método, uso ou kit, e, método, medicamento ou kit
MX2018002344A (es) Metodo para tratar el cancer.
MX2021010173A (es) Compuestos con actividad inductora de ferroptosis y métodos de uso.
MX2016007351A (es) Terapia de combinacion para tratar cancer.
MY183661A (en) Treatment of cancer with tor kinase inhibitors
CL2011000916A1 (es) Uso de una combinacion de un inhibidor de proteasoma epoxicetona peptidica o una sal farmaceutica aceptable del mismo, y uno o mas de otros agentes terapeuticos para tratar el cancer.
MX2019010601A (es) Terapia de combinacion para tratar cancer.
SG10201902664RA (en) Combination therapy for treating cancer
NZ731696A (en) Method for treating cancer
CL2015003343A1 (es) Composición farmacéutica que comprende un agente terapéutico modificado en base a hemoglobina, para el tratamiento para tratar el cáncer, e imágenes de diagnóstico.
WO2016043874A3 (en) Combination therapy for treating cancer
BR112018012255A2 (pt) método para tratar câncer
CA2908742C (en) Combination therapy comprising a tor kinase inhibitor and a cytidine analog for treating cancer
MX2012010212A (es) Terapias inhibidoras de autofagia basadas en tioxantona para tratar el cancer.
WO2019090347A8 (en) Adenosine pathway inhibitors for cancer treatment
MY176599A (en) Treatment of prostate cancer with tor kinase inhibitors
PH12019500758A1 (en) Pharmaceutical compositions and methods for the treatment of cancer
WO2021041539A3 (en) Pyrido-indole analogues as gpx4 inhibitors
MX2019003751A (es) Proteina terapeutica.